Insmed Incorporated (NASDAQ:INSM) Given Average Rating of "Buy" by Brokerages

Insmed Incorporated (NASDAQ:INSM - Get Free Report) has been assigned an average recommendation of "Buy" from the sixteen research firms that are covering the stock, Marketbeat reports. Sixteen equities research analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $82.73.

A number of research analysts recently commented on INSM shares. Morgan Stanley increased their target price on shares of Insmed from $60.00 to $85.00 and gave the company an "overweight" rating in a research report on Friday, July 12th. Bank of America raised their price objective on shares of Insmed from $84.00 to $86.00 and gave the stock a "buy" rating in a research report on Wednesday, October 9th. Cantor Fitzgerald reissued an "overweight" rating on shares of Insmed in a research report on Monday, September 9th. Stifel Nicolaus raised their price objective on shares of Insmed from $74.00 to $88.00 and gave the stock a "buy" rating in a research report on Friday, August 9th. Finally, StockNews.com downgraded shares of Insmed from a "hold" rating to a "sell" rating in a research report on Friday, August 9th.

Insmed Stock Down 0.3 %

Shares of INSM traded down $0.23 during midday trading on Thursday, reaching $71.71. The stock had a trading volume of 805,051 shares, compared to its average volume of 2,303,742. The company has a debt-to-equity ratio of 25.05, a current ratio of 2.71 and a quick ratio of 2.53. The company's fifty day simple moving average is $73.93 and its two-hundred day simple moving average is $59.51. The company has a market cap of $10.66 billion, a price-to-earnings ratio of -13.71 and a beta of 1.11. Insmed has a 1-year low of $21.92 and a 1-year high of $80.53.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing analysts' consensus estimates of ($1.22) by ($0.72). The company had revenue of $90.34 million for the quarter, compared to analysts' expectations of $87.95 million. Insmed's revenue was up 17.0% on a year-over-year basis. During the same quarter last year, the business earned ($1.78) earnings per share. Equities research analysts expect that Insmed will post -5.41 earnings per share for the current year.

Insider Activity at Insmed

In related news, insider Martina M.D. Flammer sold 13,436 shares of the firm's stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $74.92, for a total value of $1,006,625.12. Following the completion of the sale, the insider now owns 106,134 shares in the company, valued at $7,951,559.28. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the firm's stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total value of $2,686,612.50. Following the completion of the sale, the insider now owns 100,100 shares in the company, valued at $7,157,150. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Martina M.D. Flammer sold 13,436 shares of the firm's stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the completion of the sale, the insider now owns 106,134 shares of the company's stock, valued at $7,951,559.28. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 78,882 shares of company stock worth $5,765,446 over the last 90 days. Company insiders own 4.60% of the company's stock.

Hedge Funds Weigh In On Insmed

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in INSM. Darwin Global Management Ltd. acquired a new position in Insmed during the second quarter worth about $237,076,000. Capital International Investors acquired a new position in Insmed during the first quarter worth about $43,973,000. Clearbridge Investments LLC purchased a new stake in shares of Insmed during the first quarter worth about $25,242,000. Fiera Capital Corp purchased a new stake in shares of Insmed during the second quarter worth about $40,570,000. Finally, Farallon Capital Management LLC purchased a new stake in shares of Insmed during the second quarter worth about $38,056,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.